LEXICON
No.93 December 5, 2011

Drug cost ratio
薬剤費比率
National healthcare expenditure
国民医療費
Wards for recuperation under health insurance
医療(保険型)療養病棟
Wards for recuperation under nursing care insurance
介護(保険型)療養病棟
Ward charging special admission fee
特定入院料算定病棟
Ward for rehabilitation during convalescence
回復期リハビリテーション病棟

The drug cost ratio (薬剤費比率) is defined as the cost of drugs (薬剤費) used under the health insurance system (医療保険制度) as a percentage of national healthcare expenditure (国民医療費). As a rule, each ethical drug (医療用医薬品) is reimbursed at its NHI...

To read the full story

LEXICON

By Takashi Ebisawa

Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…

By Philip Carrigan

Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

By Ken Yoshino

Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…

For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…